The trajectory of Viagra presents a complex case for investors in the medicinal sector. While initially a phenomenal success, producing vast sums, the intellectual property lapse and the subsequent entry of cheaper alternatives have drastically changed earnings. This raises questions about the long-term sustainability of analogous medication projec